medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2014, Number 3

<< Back Next >>

Rev Invest Clin 2014; 66 (3)

Breast cancer in México: a 10-year trend analysis on incidence and age at diagnosis

Salinas-Martínez AM, Juárez-Ruiz A, Mathiew-Quirós Á, Guzmán-De la Garza FJ, Santos-Lartigue A, Escobar-Moreno C

Language: Spanish
References: 44
Page: 210-217
PDF size: 181.60 Kb.


ABSTRACT

Introduction. Breast cancer is an important public health problem. Some countries have achieved a downward trend while in others, continues ascending. In México, information on incidence and age at diagnosis is isolated in time, and knowledge on trend analysis is lacking. Objective. To examine the 2003-2012 trend of the incidence rate and age at diagnosis of breast cancer in the northeast of México. We also analyze the trend of positivity to nodes, hormone receptors and HER2; and its association with age at diagnosis. Material and methods. This is an epidemiological study of breast cancer patients in a tertiary care hospital in Monterrey, México (n = 3,488). Only new cases with a histology report were included; if this was not available, the cytology result was considered. Trend analysis was performed using the JoinPoint regression program Version 3.5. Results. The breast cancer incidence rate increased from 26.7 to 49.8 per 100,000 between 2003 and 2011 (p ‹ 0.05). The adjusted rate showed an annual percentage rate of change of +6.2% (95%CI 4.2, 8.2). The mean age was 55.7 ± 13.7 years and remained stable over time. Nodes, hormone receptors and HER2 positivity rate also remained stable over time. Age ‹ 50 years increased twice the risk for positivity to nodes (OR 2.0, 95%CI 1.4, 2.7), ER-PR- (OR 1.8, 95% CI 1.4, 2.4) and ER-PR-HER2- (OR 1.9, 95%CI 1.5, 2.5). Conclusions. The 10-year analysis showed a significant upward trend. This study represents a first effort in our country, for determining patterns on incidence and age at diagnosis of breast cancer, as well as that of biomarkers.


REFERENCES

  1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011; 378(9801): 1461-84.

  2. Franco-Marina F, Lazcano-Ponce E, López-Carrillo L. Breast cancer mortality in Mexico. An age-period-cohort analysis. Sal Pub Mex 2009; 51(Suppl. 2): S157-S164.

  3. Palacio-Mejía LS, Lazcano-Ponce E, Allen-Leigh B, Hernández- Ávila M. Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006. Sal Pub Mex 2009; 51(Supl. 2): S208-S219.

  4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.

  5. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007; 9: R28.

  6. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008; 188: 641-4.

  7. Fontenoy AM, Leux C, Delacour-Billon S, Allioux C, Frenel JS, Campone M, Molinié F. Recent trends in breast cancer incidence rates in the Loire-Atlantique, France: a decline since 2003. Cancer Epidemiol 2010; 34: 238-43.

  8. Renard F, Vankrunkelsven P, Van Eycken L, Henau K, Boniol M, Autier P. Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. Ann Oncol 2010; 21: 2356-60.

  9. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008; 107: 427-30.

  10. Weedon-Fekjær H, Bakken K, Vatten LJ, Tretli S. Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. BMJ 2012; 344: e299.

  11. Pollán M, Pastor-Barriuso R, Ardanaz E, Arguelles M, Martos C, Galcerán J, et al. Recent changes in breast cancer incidence in Spain, 1980–2004. J Natl Cancer Inst 2009; 101: 1584-91.

  12. Leung GM, Thach TQ, Lam TH, Hedley AJ, Foo W, Fielding R, Yip PS, Lau EM, Wong CM. Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-periodcohort analysis. Br J Cancer 2002; 87: 982-8.

  13. Shen YC, Chang CJ, Hsu C, Cheng CC, Chiu CF, Cheng AL. Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev 2005; 14: 1986-90.

  14. Tas F, Keskin S. Age-specific incidence ratios of breast cancer (BC) in Turkey: BC in older people is increasing. Arch Gerontol Geriatr 2012; 55: 112-5.

  15. Lozano-Ascencio R, Gómez-Dantés H, Lewis S, Torres-Sánchez L, López-Carrillo L. Breast cancer trends in Latin America and the Caribbean. Sal Pub Mex 2009; 51(suppl. 2): S147-S156.

  16. Anderson W, Pfeiffer RM, Dores GM, Sherman ME. Comparison of age distribution patterns for different histopathological types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 1899-905.

  17. Bernal Pérez M, Villavieja Atance L, Moros García M, Martínez Tello D, Fernández JM, Sainz Martínez JM, et al. Descenso de la edad al diagnóstico en el cáncer de mama. Prog Obstet Ginecol 2011; 54: 397-402.

  18. Eivazi-Ziaei J, Dastgiri S, Kermani IA, Nikanfar A, Esfahani A, Sanaat Z, et al. Age pattern of the occurrence of breast cancer in the northwest of Iran. Indian J Cancer 2011; 48: 406-09.

  19. Yang HJ, Yu XF, He XM, Fan JH, Li J, Xu F, et al. Age interactions in breast cancer: an analysis of a 10-year multicentre study in China. J Int Med Res 2012; 40: 1130-40.

  20. Li J, Zhang BN, Fan JH, Pang Y, Zhang P, Wang SL, et al. A nation-wide multicenter 10-year (1999-2008) retrospective Salinas-Martínez AM, et al. Incidencia de cáncer mama 2003-2012. Rev Invest Clin 2014; 66 (3): 210-217 217 clinical epidemiological study of female breast cancer in China. BMC Cancer 2011; 11: 364.

  21. Rambau PF, Chalya PL, Manyama MM, Jackson KJ. Pathological features of Breast Cancer seen in Northwestern Tanzania: a nine years retrospective study. BMC Res Notes 2011; 4: 214.

  22. Rodríguez-Cuevas S, Macías CG, Franceschi D, Labastida S. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer 2001; 91: 863-8.

  23. Rodríguez-Cuevas S, Guisa-Hohenstein F, Labastida-Almendaro S. First breast cancer mammography screening program in Mexico: initial results 2005-2006. Breast J 2009; 15: 623-31.

  24. Robles-Castillo J, Ruvalcaba-Limón E, Maffuz A, Rodríguez- Cuevas S. Cáncer de mama en mujeres mexicanas menores de 40 años. Ginecol Obstet Mex 2011; 79: 482-8.

  25. Thomas GA, Leonard RC. How age affects the biology of breast cancer. Clin Oncol (R Coll Radiol) 2009; 21: 81-5.

  26. Oh JL, Bonnen M, Outlaw ED, Schechter NR, Perkins GH, Strom EA, et al. The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: how young is “young”? Int J Radiat Oncol Biol Phys 2006; 65: 1345-52.

  27. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Statistics in Medicine 2000; 19: 335-51.

  28. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Disponible en: http://globocan iarc.fr [consultado 26 de julio 2013].

  29. Joinpoint Regression Program, Version 4.0.4 - May 2013; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute.

  30. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Disponible en: http://globocan iarc.fr [consultado el 10 de enero 2014].

  31. Séradour B, Allemand H, Weill A, Ricordeau P. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from2000 to 2006. Bull Cancer 2009; 96: E1-E6.

  32. Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, Mohar A, Bargalló E, Meneses A, et al. Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist 2013; 18(Suppl.): 26-34.

  33. Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 2013; Suppl. 1: S2-S8.

  34. Boyle T, McPadden E. Breast cancer presents at an earlier age in Mexican American women. Breast J 2004; 10: 462-4.

  35. Fouladi N, Pourfarzi F, Amani F, Ali-Mohammadi H, Lotf I, Mazaheri E. Breast cancer in Ardabil province in the northwest of Iran: an epidemiological study. Asian Pac J Cancer Prev 2012; 13: 1543-5.

  36. Najjar H, Easson A. Age at diagnosis of breast cancer in Arab nations. Int J Surg 2010; 8: 448-52.

  37. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol 2009; 169: 1251-9.

  38. Neven P, Van Calster B, Van den Bempt I, Van Huffel S, Van Belle V, Hendrickx W, et al. Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer. Breast Cancer Res Treat 2008; 110: 153-9.

  39. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population- based study from the California cancer Registry. Cancer 2007; 109: 1721-8.

  40. Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea- Ilies G, Bayakly AR, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer 2010; 116: 2549-59.

  41. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake- Cerda M, Arce C, Motola-Kuba D, Villarreal-Garza C, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 2011; 117: 3658-69.

  42. Hussein O, Mosbah M, Farouk O, Farag K, El-Saed A, Arafa M, Abdallah A. Hormone receptors and age distribution in breast cancer patients at a university hospital in Northern Egypt. Breast Cancer (Auckl) 2013; 7: 51-7.

  43. Sprague BL, Trentham-Dietz A. Prevalence of breast carcinoma in situ in the United States. JAMA 2009; 302: 846-8.

  44. Cortés Alcalá R. Registro oncológico de México (ROMex). Disponible en: http://www2.rinc-unasur.org/wps/wcm/connect/4c7f8f8040bf5fd6bze9ffb56870bbc2/MEXICO.pdf? MOD=AJPERES&CACHEID=4c7f8f8040bf5fd6bee9ffb56870 bbc2 [consultado el 9 enero 2014].




2020     |     www.medigraphic.com